Back
Home » Business
  •  
    Filmi Bollywood
    • Aaradhya Bachchan's Cute Smile Steals The Show As She Poses With Aishwarya & Abhishek!
    • Madhur Bhandarkar After Visiting Lata Mangeshkar In Hospital: 'She Is Stable'
    • Ajay Devgn Says Working With Kajol In 'Tanhaji' Felt Like Home On Sets!
    • Pati Patni Aur Woh Song 'Ankhiyon Se Goli Mare': Kartik, Bhumi & Ananya Get Groovy!
    • Mardaani 2 Director Apologises To Kota Residents After Locals Alleged It Showed Them In Bad Light!
    • Tamannaah Bhatia Gets Emotional After Meeting 'Idol' Karisma Kapoor On A Flight!
    • Italian Film ‘Despite The Fog’ Opens The 50th International Film Festival Of India
    • Mehsoos Review: Chand Mohammad’s Short Film Makes For a Good Watch
    • When Katrina Kaif Left Salman Khan Blushing!
    • IFFI 2019: Historic Culmination of 50 Golden Years
    • Sushmita Sen Birthday Special: 4 Factors That Prove The Former Miss Universe Is A Superwoman!
    • IFFI 2019 Pays Homage to 13 Film Personalities Who Left Us In Recent Past
    • IFFI 2019: Things To Know About The 50th International Film Festival of India in Goa
    • Ranveer Singh Is Deepika Padukone's 'Super Drug'; Actress Drops A New Photo Of Hubby
    • Lata Mangeshkar’s Family Slams Death Hoax: Requests To Ignore Fake Reports
    • Motichoor Chaknachoor Director Disowns Film; Warns People To Watch It At Their Own Risk!
    • Birthday Special: 5 Times Tara Sutaria Made Us Say 'Marjaavaan' With Her Stunning Clicks!
    • Manav Kaul's First Look From Saina Nehwal Biopic Leaves The Shuttler Impressed!
Should You Buy Or Sell The Infosys Stock After Whistleblower Allegations?
Good Returns | 23rd Oct, 2019 10:22 AM

Just when investors seem to have forgotten issues pertaining to Vishal Sikka's exit, questions are now being raised over corporate governance standards at Infosys.

One Board member received two anonymous complaints on September 30, 2019 one dated September 20, 2019 titled "Disturbing unethical practices" and the second undated with the title, "Whistleblower Complaint."

The undated whistleblower complaint largely deals with allegations relating to the Infosys CEO's international travel to the US and Mumbai. Additionally, on October 16, 2019 the Company was made aware of a letter dated October 3, 2019 which was purportedly written to the Office of Whistleblower protection program, Washington D.C.

This letter refers to the September 20, 2019 complaint, and to emails and voice recordings in support of the allegations.

One letter also states, "In (the) last quarter (July-September), we were asked not to fully recognise costs like visa costs to improve profits. We have voice recordings of these conversations,"

In any case, there are few more allegations in the whistleblower letter.

Should Infosys shareholders hold the stock?

The shares of Infosys plunged 16 per cent on Tuesday, following the whistleblower allegations. While the allegations are serious, Infosys has appointed a law firm and an audit firm to look into the same. One will have to wait to see what comes out of the investigations.

Investors should really worry whether things will change fundamentally after these allegations. To begin with the allegations are not likely to see too much of an impact on the bottomline of the company.

However, if perception of poor governance gathers steam, Infosys might find it difficult to win new clients and retain contracts. The resignation of the Deputy CFO last week has only raised concerns further, though it may not be linked to the present whistleblower allegations.

There are now reports that a US law firm is preparing class-action suit against Infosys, which could put further pressure on the stock. There could be a sudden re-rating of the stock and we could see price to earnings multiples contract.

The one thing that investors would need to wait for is the conclusion of the investigations. One is not sure what could come out of these allegations. It would be nice if Infosys could specify a clear time by which the investigations could be complete. At the moment, you might not want to bet on the stock, unless there is a further sharp re-rating.

The outcome of the investigations could also lead to uncertainty at the top, which could have an impact growth. Credit Suisse has given an underperform rating on the stock, while UBS says it remains neutral.

However, at the current price of Rs 643, we still see an element of risk of price to earnings multiple shrinking. There could also be a bounceback in the stock on short covering rally, which should be used to sell the stock.

Should the stock fall a good 10 per cent from here, it could become attractive for its dividend yield. Is all about entering the stock at the right price and that could be a dip below Rs 600.

Infosys, still gives a dividend yield of around 3.5 per cent, which is as good as interest on a savings bank account.

GoodReturns.in

   
 
Health and Life
  • Copaiba Oil: Health Benefits, Risks And How To Use
  • Bleeding Haemorrhoids (Piles): Symptoms, Prevention And Ways To Manage It
  • Neurosexism: Is It True That Men And Women Have Different Brains?
    • 6 Surprising Health Benefits Of Black Sapote
    • Erythritol: Health Benefits And Side Effects
    • Dysphagia (Swallowing Difficulty): Types, Symptoms, Causes, Risk Factors, Diagnosis And Treatment
      • Is Dosa Good For A Weight-loss Diet?
      • 10 Best Quadriceps Exercises To Strengthen Your Thighs
      • 6 Impressive Health Benefits Of Buckwheat Tea
        • Heat Exhaustion: Types, Symptoms, Causes, Risk Factors, Diagnosis, Treatment And Prevention
        • Diabetes Insipidus In Children: Causes, Types, Symptoms, Diagnosis And Treatment
        • World Diabetes Day 2019: Best And Worst Drinks For Diabetes
          • Diabetes-friendly Indian Diet: A 7-day Vegetarian And Non-vegetarian Meal Plan
          • Diabetes Insipidus: Causes, Symptoms, Diagnosis, Treatment And Prevention
          • World Diabetes Day 2019: Expert Tips To Eat Right And Manage Diabetes
            • Juvenile Diabetes: Symptoms, Causes, Risk Factors And How To Manage
            • Kava: Health Benefits, Side Effects And How To Use
            • Diabetic Foot Ulcers: Causes, Types, Symptoms, Diagnosis, Treatment And How To Prevent Them
              • Syphilis: Causes, Symptoms, Diagnosis & Treatment
              • 11 Proven Health Benefits Of Honeybush Tea
              • 10 Surprising Health Benefits Of Nectarines